Encoded Therapeutics is currently preparing for clinical trials using ETX101 for SCN1A-positive Dravet syndrome patients.1 The gene discussed is SCN1A; the disease is encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy.